Scilex 8/13/2025 Earnings Report

Scilex EPS Results

• Actual EPS: -$7.42
• Consensus EPS: -$4.55
• Beat/Miss: Missed by -$2.87
• One Year Ago EPS: N/A

Scilex Revenue Results

• Actual Revenue: $9.90 million
• Expected Revenue: $26.25 million
• Beat/Miss: Missed by -$16.35 million
• YoY Revenue Growth: N/A

Scilex Announcement Details

• Date: 8/13/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Scilex (NASDAQ:SCLX) focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.